Alexandria Real Estate Equities, the largest owner of life-science laboratory space in the country, priced a $1 billion offering of long-dated subordinated notes this week, tapping the debt markets at a 7.25% coupon as the REIT works to shore up its balance sheet following a difficult stretch for lab-space demand.
The notes, formally called 7.250% Series A Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2057, priced at 100% of face value on Aug. 12, according to a pricing term sheet filed with the Securities and Exchange Commission. The offering is expected to settle Aug. 21.
The notes carry an initial fixed rate of 7.25% through Feb. 15, 2032. After that date, the rate resets every five years to the five-year U.S. Treasury rate plus a spread of 2.889%, though it cannot reset below the 7.25% floor. The notes mature in 2057 β a 30-plus year instrument β and are guaranteed on a subordinated basis by Alexandria’s operating partnership. Moody’s and S&P have assigned expected ratings of Baa3 and BBB-, respectively, both in investment-grade territory but near the lower end of that range, reflecting the subordinated structure of the debt.
Notably, the notes include an optional deferral feature allowing Alexandria to defer interest payments for up to five consecutive years without triggering default, a structural feature more common in preferred-equity-like hybrid securities than in conventional corporate bonds. The term sheet also permits the company to pay a “Permitted REIT Status Dividend” during any deferral period β a provision designed to let Alexandria preserve its REIT tax status, which requires distributing the bulk of its taxable income to shareholders, even if it temporarily stops paying interest on the notes.
A large syndicate of banks underwrote the deal, led by J.P. Morgan Securities, BofA Securities, Citigroup Global Markets, Goldman Sachs and RBC Capital Markets as joint book-running managers, alongside eight additional joint managers and seven co-managers. Alexandria said it intends to use the proceeds for general corporate purposes.
The offering comes as Alexandria works through a challenging period for its core life-science real estate business. The REIT posted a second-quarter loss driven by property impairments even as it held its full-year 2026 guidance, reflecting continued softness in demand for laboratory and office space from biotech tenants amid a broader pullback in life-science venture funding since 2022. Raising long-dated, fixed-rate capital at a locked-in rate for at least six years gives the company a predictable cost of capital regardless of where short-term rates move over that period.
The deal adds to a busy year of REIT capital-markets activity across the sector, from portfolio acquisitions such as H&R REIT’s $6.7 billion split with GO Residential REIT and Blackstone to a steady stream of debt and equity issuance as landlords refinance maturities in a higher-rate environment than they faced five years ago.
What it means: A 7.25% coupon on 30-year subordinated debt is expensive money by the standards of Alexandria’s pre-2022 borrowing costs, underscoring how much more REITs now pay to raise long-term capital even when, as here, the debt carries investment-grade ratings. The deferral option and REIT-dividend carve-out suggest Alexandria and its underwriters built in flexibility for a scenario where operating cash flow tightens further β a hedge that costs the company in yield today but preserves optionality if life-science leasing conditions do not recover as quickly as the company’s current guidance assumes.
